Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 6
Submit an article Journal homepage
190
Views
0
CrossRef citations to date
0
Altmetric
Review

Enhancement of Dendritic Cells as Vaccines for Cancer

Meghan E Turnis1 Baylor College of Medicine, Houston, TX, USA
&
Cliona M Rooney1 Baylor College of Medicine, Houston, TX, USACorrespondence[email protected]
Pages 847-862 | Published online: 22 Nov 2010

Bibliography

  • Forster R , SchubelA, BreitfeldD et al.: CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs.Cell99(1) , 23–33 (1999).
  • Sanchez-Sanchez N , Riol-BlancoL, Rodriguez-FernandezJL: The multiple personalities of the chemokine receptor CCR7 in dendritic cells.J. Immunol.176(9) , 5153–5159 (2006).
  • Steinman RM : Some interfaces of dendritic cell biology.APMIS111(7–8) , 675–697 (2003).
  • Banchereau J , SteinmanRM: Dendritic cells and the control of immunity.Nature392(6673) , 245–252 (1998).
  • Luo J , SoliminiNL, ElledgeSJ: Principles of cancer therapy: oncogene and non-oncogene addiction.Cell136(5) , 823–837 (2009).
  • Bronte V , MocellinS: Suppressive influences in the immune response to cancer.J. Immunother.32(1) , 1–11 (2009).
  • Hsu FJ , BenikeC, FagnoniF et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.Nat. Med.2(1) , 52–58 (1996).
  • Nestle FO , AlijagicS, GillietM et al..: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med.4(3) , 328–332 (1998).
  • Di Nicola M , Carlo-StellaC, MortariniR et al.: Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination: a Phase I trial in metastatic melanoma.Clin. Cancer Res.10(16) , 5381–5390 (2004).
  • Fay JW , PaluckaAK, PaczesnyS et al.: Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells.Cancer Immunol. Immunother.55(10) , 1209–1218 (2006).
  • Reichardt VL , BrossartP, KanzL: Dendritic cells in vaccination therapies of human malignant disease.Blood Rev.18(4) , 235–243 (2004).
  • Anguille S , SmitsEL, CoolsN, GoossensH, BernemanZN, Van Tendeloo V: Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J. Transl. Med.7 , 109 (2009).
  • Trakatelli M , ToungouzM, BlockletD et al.: A new dendritic cell vaccine generated with interleukin-3 and interferon-β induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients.Cancer Immunol. Immunother.55(4) , 469–474 (2006).
  • Jonuleit H , KuhnU, MullerG et al.: Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions.Eur. J. Immunol.27(12) , 3135–3142 (1997).
  • Ridgway D : The first 1000 dendritic cell vaccinees.Cancer Invest.21(6) , 873–886 (2003).
  • Palucka AK , UenoH, FayJ, BanchereauJ: Harnessing dendritic cells to generate cancer vaccines.Ann. NY Acad. Sci.1174 , 88–98 (2009).
  • Grover A , KimGJ, LizeeG et al.: Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.Clin. Cancer Res.12(19) , 5801–5808 (2006).
  • Lesimple T , NeidhardEM, VignardV et al.: Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.Clin. Cancer Res.12(24) , 7380–7388 (2006).
  • Maier T , Tun-KyiA, TassisA et al.: Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells.Blood102(7) , 2338–2344 (2003).
  • Dannull J , SuZ, RizzieriD et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.J. Clin. Invest.115(12) , 3623–3633 (2005).
  • Gilboa E , ViewegJ: Cancer immunotherapy with mRNA-transfected dendritic cells.Immunol. Rev.199 , 251–263 (2004).
  • Pecher G , HaringA, KaiserL, ThielE: Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a Phase I/II clinical trial.Cancer Immunol. Immunother.51(11–12) , 669–673 (2002).
  • Butterfield LH , Comin-AnduixB, VujanovicL et al.: Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.J. Immunother.31(3) , 294–309 (2008).
  • Morse MA , ClayTM, HobeikaAC et al.: Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.Clin. Cancer Res.11(8) , 3017–3024 (2005).
  • Paczesny S , BanchereauJ, WittkowskiKM, SaracinoG, FayJ, PaluckaAK: Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells.J. Exp. Med.199(11) , 1503–1511 (2004).
  • Wierecky J , MullerMR, WirthsS et al.: Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.Cancer Res.66(11) , 5910–5918 (2006).
  • Kern F , FaulhaberN, FrommelC et al.: Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides.Eur. J. Immunol.30(6) , 1676–1682 (2000).
  • Timmerman JM , CzerwinskiDK, DavisTA et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.Blood99(5) , 1517–1526 (2002).
  • Curti A , TosiP, ComoliP et al.: Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.Br. J. Haematol.139(3) , 415–424 (2007).
  • Heiser A , ColemanD, DannullJ et al.: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.J. Clin. Invest.109(3) , 409–417 (2002).
  • Palucka AK , UenoH, ConnollyJ et al.: Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.J. Immunother.29(5) , 545–557 (2006).
  • Di Nicola M ., Zappasodi R, Carlo-Stella C et al.: Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood113(1) , 18–27 (2009).
  • Von Euw EM , BarrioMM, FurmanD et al.: A Phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression.J. Transl. Med.6 , 6 (2008).
  • Su Z , DannullJ, HeiserA et al.: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.Cancer Res.63(9) , 2127–2133 (2003).
  • Avigan DE , VasirB, GeorgeDJ et al.: Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.J. Immunother.30(7) , 749–761 (2007).
  • Zehn D , CohenCJ, ReiterY, WaldenP: Extended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigen-presenting cells.Eur. J. Immunol.34(6) , 1551–1560 (2004).
  • Yang L , YangH, RideoutK et al.: Engineered lentivector targeting of dendritic cells for in vivo immunization.Nat. Biotechnol.26(3) , 326–334 (2008).
  • Breckpot K , AertsJL, ThielemansK: Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics.Gene Ther.14(11) , 847–862 (2007).
  • Tsang KY , PalenaC, YokokawaJ et al.: Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.Clin. Cancer Res.11(4) , 1597–1607 (2005).
  • Knippertz I , HesseA, SchunderT et al.: Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-γ.J. Immunother.32(5) , 524–538 (2009).
  • Fattori E , AurisicchioL, ZampaglioneI et al.: ErbB2 genetic cancer vaccine in nonhuman primates: relevance of single nucleotide polymorphisms.Hum. Gene Ther.20(3) , 253–265 (2009).
  • Akira S , UematsuS, TakeuchiO: Pathogen recognition and innate immunity.Cell124(4) , 783–801 (2006).
  • Trinchieri G : Interleukin-12 and the regulation of innate resistance and adaptive immunity.Nat. Rev. Immunol.3(2) , 133–146 (2003).
  • Shortman K , NaikSH: Steady-state and inflammatory dendritic-cell development.Nat. Rev. Immunol.7(1) , 19–30 (2007).
  • Dhodapkar MV , SteinmanRM, KrasovskyJ, MunzC, BhardwajN: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells.J. Exp. Med.193(2) , 233–238 (2001).
  • Sozzani S : Dendritic cell trafficking: more than just chemokines.Cytokine Growth Factor Rev.16(6) , 581–592 (2005).
  • Randolph GJ , Sanchez-SchmitzG, AngeliV: Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances.Springer Semin. Immunopathol.26(3) , 273–287 (2005).
  • Ohl L , MohauptM, CzelothN et al.: CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions.Immunity21(2) , 279–288 (2004).
  • deVries I , KrooshoopDJ, ScharenborgNM et al.: Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.Cancer Res.63(1) , 12–17 (2003).
  • Verdijk P , AarntzenEH, LesterhuisWJ et al.: Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.Clin. Cancer Res.15(7) , 2531–2540 (2009).
  • Martin-Fontecha A , SebastianiS, HopkenUE et al.: Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming.J. Exp. Med.198(4) , 615–621 (2003).
  • Elliott B , ScolyerRA, SuciuS et al.: Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma.Clin. Cancer Res.13(13) , 3825–3830 (2007).
  • Mule JJ : Dendritic cell-based vaccines for pancreatic cancer and melanoma.Ann. NY Acad. Sci.1174 , 33–40 (2009).
  • Berntsen A , TrepiakasR, WenandyL et al.: Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical Phase 1/2 trial.J. Immunother.31(8) , 771–780 (2008).
  • Kaka AS , FosterAE, WeissHL, RooneyCM, LeenAM: Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale.J. Immunother.31(4) , 359–369 (2008).
  • Song XT , Evel-KablerK, ShenL, RollinsL, HuangXF, ChenSY: A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression.Nat. Med.14(3) , 258–265 (2008).
  • Bonehill A , Van Nuffel AM, Corthals J et al.: Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin. Cancer Res.15(10) , 3366–3375 (2009).
  • Lapteva N , SeethammagariMR, HanksBA et al.: Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation.Cancer Res.67(21) , 10528–10537 (2007).
  • Boczkowski D , LeeJ, PruittS, NairS: Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy.Cancer Gene Ther.16(12) , 900–911 (2009).
  • Keller AM , SchildknechtA, XiaoY, van den Broek M, Borst J: Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity29(6) , 934–946 (2008).
  • Keller AM , XiaoY, PeperzakV, NaikSH, BorstJ: Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting.Blood113(21) , 5167–5175 (2009).
  • Krause P , BrucknerM, UermosiC, SingerE, GroettrupM, LeglerDF: Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4–1BBL on dendritic cells.Blood113(11) , 2451–2460 (2009).
  • Bonehill A , TuyaertsS, Van Nuffel AM et al.: Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol. Ther.16(6) , 1170–1180 (2008).
  • Salem ML , KadimaAN, ZhouY et al.: Paracrine release of IL-12 stimulates IFN-γ production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine.J. Immunol.172(9) , 5159–5167 (2004).
  • Okada N , IiyamaS, OkadaY et al.: Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.Cancer Gene Ther.12(1) , 72–83 (2005).
  • Tatsumi T , HuangJ, GoodingWE et al.: Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.Cancer Res.63(19) , 6378–6386 (2003).
  • Saika T , SatohT, KusakaN et al.: Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model.Cancer Gene Ther.11(5) , 317–324 (2004).
  • Nukiwa M , AndariniS, ZainiJ et al.: Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.Eur. J. Immunol.36(4) , 1019–1027 (2006).
  • Yang SC , BatraRK, HillingerS et al.: Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma.Cancer Res.66(6) , 3205–3213 (2006).
  • Wiethe C , DittmarK, DoanT, LindenmaierW, TindleR: Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-κB (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen.J. Immunol.171(8) , 4121–4130 (2003).
  • Steel JC , RamloganCA, YuP et al.: Interleukin-15 signaling augments dendritic cell vaccination against HER2/Neu by inducing Her2/Neu antibodies.Cancer Res.70(3) , 1072–1081 (2010).
  • Park D , LaptevaN, SeethammagariM, SlawinKM, SpencerDM: An essential role for Akt1 in dendritic cell function and tumor immunotherapy.Nat. Biotechnol.24(12) , 1581–1590 (2006).
  • Chen M , HuangL, ShabierZ, WangJ: Regulation of the lifespan in dendritic cell subsets.Mol. Immunol.44(10) , 2558–2565 (2007).
  • Hou WS , Van Parijs L: A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat. Immunol.5(6) , 583–589 (2004).
  • Kang TH , LeeJH, NohKH et al.: Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments.Int. J. Cancer120(8) , 1696–1703 (2007).
  • Kim JH , KangTH, NohKH et al.: Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8+ T cell-mediated cell death.Immunol. Lett.122(1) , 58–67 (2009).
  • Evel-Kabler K , SongXT, AldrichM, HuangXF, ChenSY: SOCS1 restricts dendritic cells‘ ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling.J. Clin. Invest.116(1) , 90–100 (2006).
  • Shen L , Evel-KablerK, StrubeR, ChenSY: Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity.Nat. Biotechnol.22(12) , 1546–1553 (2004).
  • Hong B , RenW, SongXT, Evel-KablerK, ChenSY, HuangXF: Human suppressor of cytokine signaling 1 controls immunostimulatory activity of monocyte-derived dendritic cells.Cancer Res.69(20) , 8076–8084 (2009).
  • Breckpot K , Aerts-ToegaertC, HeirmanC et al.: Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine.J. Immunol.182(2) , 860–870 (2009).
  • Kobayashi K , HernandezLD, GalanJE, JanewayCA Jr, Medzhitov R, Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell110(2) , 191–202 (2002).
  • Li H , CuartasE, CuiW et al.: IL-1 receptor-associated kinase M is a central regulator of osteoclast differentiation and activation.J. Exp. Med.201(7) , 1169–1177 (2005).
  • Deng JC , ChengG, NewsteadMW et al.: Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M.J. Clin. Invest.116(9) , 2532–2542 (2006).
  • Tazi KA , QuiocJJ, SaadaV, BezeaudA, LebrecD, MoreauR: Upregulation of TNF-α production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M.J. Hepatol.45(2) , 280–289 (2006).
  • Wiersinga WJ , van‘t Veer C, van den Pangaart PS et al.: Immunosuppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Crit. Care Med.37(2) , 569–576 (2009).
  • Turnis ME , SongXT, BearA et al.: IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity.J. Immunol.185 , 4223–4232 (2010).
  • Arredouani MS , FrancoF, ImrichA et al.: Scavenger Receptors SR-AI/II and MARCO limit pulmonary dendritic cell migration and allergic airway inflammation.J. Immunol.178(9) , 5912–5920 (2007).
  • Colonna M : TREMs in the immune system and beyond.Nat. Rev. Immunol.3(6) , 445–453 (2003).
  • Graham LM , BrownGD: The Dectin-2 family of C-type lectins in immunity and homeostasis.Cytokine48(1–2) , 148–155 (2009).
  • Meyer-Wentrup F , Benitez-RibasD, TackenPJ et al.: Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-α production.Blood111(8) , 4245–4253 (2008).
  • Cao W , ZhangL, RosenDB et al.: BDCA2/Fc ε RI γ complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells.PLoS Biol.5(10) , E248 (2007).
  • Matsushita N , KomineH, Grolleau-JuliusA, Pilon-ThomasS, MuleJJ: Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.Cancer Immunol. Immunother.59(6) , 875–884. (2010).
  • Bonifaz L , BonnyayD, MahnkeK, RiveraM, NussenzweigMC, SteinmanRM: Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.J. Exp. Med.196(12) , 1627–1638 (2002).
  • Charalambous A , OksM, NchindaG, YamazakiS, SteinmanRM: Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin.J. Immunol.177(12) , 8410–8421 (2006).
  • Steinman RM : Dendritic cells in vivo: a key target for a new vaccine science.Immunity29(3) , 319–324 (2008).
  • Caminschi I , ProiettoAI, AhmetF et al.: The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement.Blood112(8) , 3264–3273 (2008).
  • Sancho D , Mourao-SaD, JoffreOP et al.: Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin.J. Clin. Invest.118(6) , 2098–2110 (2008).
  • Pilon-Thomas S , MackayA, VohraN, MuleJJ: Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.J. Immunol.184(7) , 3442–3449 (2010).
  • Koike N , Pilon-ThomasS, MuleJJ: Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma.J. Immunother.31(4) , 402–412 (2008).
  • Schwaab T , SchwarzerA, WolfB et al.: Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (interleukin 2) and IFN-α2a therapy in metastatic renal cell carcinoma patients.Clin. Cancer Res.15(15) , 4986–4992 (2009).
  • Haas AR , SunJ, VachaniA et al.: Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine.Clin. Cancer Res.12(1) , 214–222 (2006).
  • Sharma MD , HouDY, LiuY et al.: Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes.Blood113(24) , 6102–6111 (2009).
  • Sharma S , StolinaM, YangSC et al.: Tumor cyclooxygenase 2-dependent suppression of dendritic cell function.Clin. Cancer Res.9(3) , 961–968 (2003).
  • Morse MA , HobeikaAC, OsadaT et al.: Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.Blood112(3) , 610–618 (2008).
  • Brenk M , SchelerM, KochS et al.: Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+ Foxp3+ T regulatory cells.J. Immunol.183(1) , 145–154 (2009).
  • Ward RC , KaufmanHL: Targeting costimulatory pathways for tumor immunotherapy.Int. Rev. Immunol.26(3–4) , 161–196 (2007).
  • Attia P , PhanGQ, MakerAV et al.: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.J. Clin. Oncol.23(25) , 6043–6053 (2005).
  • Downey SG , KlapperJA, SmithFO et al.: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.Clin. Cancer Res.13(22 Pt 1) , 6681–6688 (2007).
  • Chakraborty M , SchlomJ, HodgeJW: The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses.Cancer Immunol. Immunother.56(9) , 1471–1484 (2007).
  • Curran MA , AllisonJP: Tumor vaccines expressing FLT3 ligand synergize with CTLA-4 blockade to reject preimplanted tumors.Cancer Res.69(19) , 7747–7755 (2009).
  • Iinuma T , HommaS, NodaT, KufeD, OhnoT, TodaG: Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine.J. Clin. Invest.113(9) , 1307–1317 (2004).
  • Mukherjee P , BasuGD, TinderTL et al.: Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.J. Immunol.182(1) , 216–224 (2009).
  • Rapoport AP , StadtmauerEA, AquiN et al.: Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.Nat. Med.11(11) , 1230–1237 (2005).
  • Wheeler CJ , BlackKL, LiuG et al.: Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.Cancer Res.68(14) , 5955–5964 (2008).
  • Leen AM , RooneyCM, FosterAE: Improving T cell therapy for cancer.Annu. Rev. Immunol.25 , 243–265 (2007).
  • Loveland BE , ZhaoA, WhiteS et al.: Mannan-MUC1-pulsed dendritic cell immunotherapy: a Phase I trial in patients with adenocarcinoma.Clin. Cancer Res.12(3 Pt 1) , 869–877 (2006).
  • Maraskovsky E , SjolanderS, DraneDP et al.: NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1+ tumors.Clin. Cancer Res.10(8) , 2879–2890 (2004).
  • Morse MA , HobeikaA, OsadaT et al.: Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.J. Transl. Med.5 , 42 (2007).
  • Shi L , LuoK, XiaD et al.: DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses.Blood108(8) , 2678–2686 (2006).
  • Chang CC , CiubotariuR, ManavalanJS et al.: Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4.Nat. Immunol.3(3) , 237–243 (2002).
  • Chang CC , LiuZ, VladG et al.: Ig-like transcript 3 regulates expression of proinflammatory cytokines and migration of activated T cells.J. Immunol.182(9) , 5208–5216 (2009).
  • Endo S , SakamotoY, KobayashiE, NakamuraA, TakaiT: Regulation of cytotoxic T lymphocyte triggering by PIR-B on dendritic cells.Proc. Natl Acad. Sci. USA105(38) , 14515–14520 (2008).
  • Zhang H , MengF, ChuCL, TakaiT, LowellCA: The Src family kinases Hck and Fgr negatively regulate neutrophil and dendritic cell chemokine signaling via PIR-B.Immunity22(2) , 235–246 (2005).
  • Benedict CA , LoewendorfA, GarciaZ, BlazarBR, JanssenEM: Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway.J. Immunol.180(7) , 4836–4847 (2008).
  • Butte MJ , KeirME, PhamduyTB, SharpeAH, FreemanGJ: Programmed death-1 ligand 1 interacts specifically with the B7–1 costimulatory molecule to inhibit T cell responses.Immunity27(1) , 111–122 (2007).
  • Curiel TJ , WeiS, DongH et al.: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.Nat. Med.9(5) , 562–567 (2003).
  • Kim HK , GuanH, ZuG et al.: High-level expression of B7-H1 molecules by dendritic cells suppresses the function of activated T cells and desensitizes allergen-primed animals.J. Leukoc. Biol.79(4) , 686–695 (2006).
  • Fukunaga A , NagaiH, NoguchiT et al.: Src homology 2 domain-containing protein tyrosine phosphatase substrate 1 regulates the migration of Langerhans cells from the epidermis to draining lymph nodes.J. Immunol.172(7) , 4091–4099 (2004).
  • Latour S , TanakaH, DemeureC et al.: Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-α: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation.J. Immunol.167(5) , 2547–2554 (2001).
  • Fujikado N , SaijoS, YonezawaT et al.: Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells.Nat. Med.14(2) , 176–180 (2008).
  • Chen CH , FloydH, OlsonNE et al.: Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production.Blood107(4) , 1459–1467 (2006).
  • Pyz E , HuysamenC, MarshallAS, GordonS, TaylorPR, BrownGD: Characterisation of murine MICL (CLEC12A) and evidence for an endogenous ligand.Eur. J. Immunol.38(4) , 1157–1163 (2008).
  • Behrens EM , SriramU, ShiversDK et al.: Complement receptor 3 ligation of dendritic cells suppresses their stimulatory capacity.J. Immunol.178(10) , 6268–6279 (2007).
  • Skoberne M , SomersanS, AlmodovarW et al.: The apoptotic-cell receptor CR3, but not avb5, is a regulator of human dendritic-cell immunostimulatory function.Blood108(3) , 947–955 (2006).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.